glp-1 heart failure medications are not just for weight loss — they are the most important drug class of our lifetime. 🫀 A 2025 meta-analysis of 99,599 patients confirmed: ✓ 20% reduction in major GLP-1 and the cardiovascular system

What are the key differences between Orforglipron and Semaglutide

It helps improve blood sugar, metabolism, and cardiovascular health, and it has anti-inflammatory properties that can affect biomarkers

Our experience suggests that while a systemic dose will eventually reach the ankle, a localized dose may create a much higher concentration gradient in the target tissue for a more potent and immediate effect

The study, which ended prematurely due to a higher mortality rate in the intensive treatment group, failed to report significant reduction in major cardiovascular events, giving a notion that intensive therapy was associated with significant harm in high risk patients [6]

Wengrod, J

I don't need substance to enjoy it